SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess
of $100,000 From Investment in Amyris, Inc. to Contact Brower Piven Before the
July 15, 2013 Lead Plaintiff Deadline -- AMRS
STEVENSON, Md., May 17, 2013 (GLOBE NEWSWIRE) -- Brower Piven, A Professional
Corporation announces that a class action lawsuit has been commenced in the
United States District Court for the Northern District of California on behalf
of purchasers of Amyris, Inc. ("Amyris" or the "Company") (Nasdaq:AMRS) common
stock during the period between April 29, 2011 and February 8, 2012, inclusive
(the "Class Period").
If you have suffered a net loss from investment in Amyris, Inc. common stock
purchased on or after April 29, 2011, and held through any of the revelations
of negative information on November 1, 2011 and/or February 9, 2012, as
described below, you may obtain additional information about this lawsuit and
your ability to become a lead plaintiff by contacting Brower Piven at
www.browerpiven.com, by email at firstname.lastname@example.org, by calling
410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley
Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined
experience litigating securities and class action cases of over 60 years.
No class has yet been certified in the above action.Members of the Class will
be represented by the lead plaintiff and counsel chosen by the lead
plaintiff.If you wish to choose counsel to represent you and the Class, you
must apply to be appointed lead plaintiff no later than July 15, 2013 and be
selected by the Court.The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a settlement
and how much of a settlement to accept for the Class in the action. The lead
plaintiff will be selected from among applicants claiming the largest loss
from investment in the Company during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange
Act of 1934 by virtue of the defendants falsely representing during the Class
Period that the Company had the ability to produce Biofene in commercially
meaningful volumes.According to the complaint, following the Company's
November 1, 2011 disclosure that it would not be able to produce Biofene in
the quantities previously represented but that it had identified and learned
to address issues that would allow it to raise the volumes, and the Company's
February 9, 2012 disclosure of a further slowdown in Biofene production and
the need to raise funds, the value of Amyris shares declined significantly.
If you choose to retain counsel, you may retain Brower Piven without financial
obligation or cost to you, or you may retain other counsel of your choice.You
need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
Press spacebar to pause and continue. Press esc to stop.